Plain-English translation of NCT06529523 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Colorectal Cancer research guide βPhase 2 β Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help treat colorectal cancer in people living in Nigeria. works by helping your immune system recognize and fight cancer cells. The study will look at how well the medication works and how safe it is for people with a specific type of colorectal cancer called mismatch-repair deficient cancer.
Mismatch-repair deficient colorectal cancer is a type that is harder to treat with standard therapies. Researchers believe this medication, which works differently by boosting the immune system, may be more effective for this particular cancer type.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you join this study, you will receive the medication through an IV (intravenous) infusion every 3 weeks. Your first infusion will take about 1 hour, and future ones will take about 30 minutes. You will need to visit the clinic regularly for infusions and checkups to monitor how you are responding to treatment and to watch for any side effects. The study will track your cancer's response to the medication over time.
AI-generated summary from trial data Β· Sep 18, 2026 Β· Not medical advice
United States
Nigeria